Becton Dickinson & (BDX) Stock
Global medical technology firm supplying devices and instruments. Here's the price, business snapshot, and what's worth knowing about Becton Dickinson & in September 2026.
Becton, Dickinson and Company (BDX) is a global medical technology firm supplying devices, instruments and reagents used by hospitals, laboratories and life‑science researchers. Its portfolio includes needles and syringes, medication‑management systems, diagnostic instruments and biosciences tools, producing a high share of recurring revenue and relatively predictable cash flows. With a market capitalisation of around $54.18 billion, BDX benefits from steady demand driven by hospital procedures, chronic disease management and diagnostic testing. Investors tend to focus on margin trends, capital allocation (dividends and buybacks), R&D and acquisition activity. Key risks include regulatory scrutiny, litigation, reimbursement pressure and sensitivity to hospital capital spending and global economic conditions. Longer‑term growth is supported by demographic trends and ongoing innovation in diagnostics, though past performance is not a reliable indicator of future returns. This is general educational information only and not personalised investment advice; suitability depends on your individual circumstances.
Why It’s Moving
BDX draws attention as improving core growth offsets lingering cost and pricing pressure.
- BD highlighted improving traction in its slimmer portfolio, with stronger growth and margins in several core businesses helping offset pressure from legacy comparisons and pricing headwinds.
- The company’s latest quarterly update showed revenue up 5.4% and adjusted EPS up 4.9%, reinforcing the view that the turnaround is gaining momentum even as tariffs and higher costs still weigh on margins.
- A fresh dividend record date and upcoming healthcare conference appearance are keeping attention on BD’s cash returns and management commentary, while recent fund flows suggest institutional interest remains active.
BDX draws attention as improving core growth offsets lingering cost and pricing pressure.
- BD highlighted improving traction in its slimmer portfolio, with stronger growth and margins in several core businesses helping offset pressure from legacy comparisons and pricing headwinds.
- The company’s latest quarterly update showed revenue up 5.4% and adjusted EPS up 4.9%, reinforcing the view that the turnaround is gaining momentum even as tariffs and higher costs still weigh on margins.
- A fresh dividend record date and upcoming healthcare conference appearance are keeping attention on BD’s cash returns and management commentary, while recent fund flows suggest institutional interest remains active.
Sixth Month Growth Performance
When is the next earnings date for BECTON DICKINSON & CO (BDX)?
The next earnings date for BDX is expected on November 5, 2026, based on its historical reporting pattern. That release should cover fiscal Q4 2026 results. The company has not formally confirmed the date yet, so the timing could still shift slightly.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Becton Dickinson's stock, with a target price indicating significant growth potential.
Financial Health
Becton Dickinson is performing well, with strong revenue, cash flow, and profit margins.
Dividend
Becton Dickinson's dividend yield of 2.27% is moderate, providing a reasonable return for dividend-seeking investors. If you invested $1000 you would be paid $22.70 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Recurring Revenue Base
BDX earns steady income from disposables and consumables which can smooth earnings, though results can still vary with hospital budgets and competition.
Global Healthcare Exposure
Sales span hospitals, labs and research centres worldwide, offering diversification but exposing the company to currency and regulatory risks.
Innovation & M&A
R&D and targeted acquisitions help expand the product pipeline and market share, though integration and regulatory hurdles can affect outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
